Market Overview

UPDATE: Citigroup Reiterates Illumina at Neutral on Valuation

Share:
Related ILMN
Pressure From Japan: Interest Rate Decision Weighs, But Earnings In Focus
Departure Of TrovaGene CCO Creates Near-Term Risks; Cantor Downgrades Stock

Citigroup maintained Illumina (NASDAQ: ILMN) at Neutral with a $51 price target.

Citigroup commented, "We expect the stock to be under pressure today as investors question the deal valuation/near-term $0.20 EPS dilution of the Verinata deal, the longer term impact of ILMN competing with its own customers (i.e., SQNM), and the level (if any) of Roche takeout premium to still ascribe to the stock. We remain on the sidelines on ILMN stock given the stock's current multiple and level of investment required/EPS power for the company in 2013."

Illumina closed at $54.76 on Friday.

Latest Ratings for ILMN

DateFirmActionFromTo
Apr 2016BarclaysMaintainsEqual-weight
Apr 2016Morgan StanleyMaintainsEqual-weight
Apr 2016Bank of AmericaDowngradesBuyNeutral

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (ILMN)

View Comments and Join the Discussion!